Engineered immune cells take on virus-driven cancers in early trial
Disease control
Recruiting now
This study tests a new treatment called GP350 CAR-T cells for people with blood cancers that are linked to the Epstein-Barr virus and have not responded to standard therapy. The treatment involves collecting a patient's own immune cells, modifying them to better target the cancer…
Phase: PHASE1, PHASE2 • Sponsor: Zhimin Zhai • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC